Literature DB >> 11725377

Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.

P Husa1, L Husova.   

Abstract

Hepatitis C is a major health problem. In recent years, the treatment of choice is alpha-interferon in combination with ribavirin. For patients with failure of this treatment the therapy with consensus or pegylated interferons, in monotherapy or in combination with ribavirin, present other possibilities. We can expect the development more potent antiviral drugs or immune modulators for patients, which are primary resistant to alpha-interferon. (Tab. 3, Ref. 31)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11725377

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  3 in total

1.  Biodegradable nanogels for oral delivery of interferon for norovirus infection.

Authors:  Yunjeong Kim; Mahendra Thapa; Duy H Hua; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2010-12-07       Impact factor: 5.970

2.  Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model.

Authors:  Qiu-Xia Fu; Li-Cui Wang; Shuai-Zheng Jia; Bo Gao; Yong Zhou; Juan Du; Ying-Li Wang; Xiao-Hui Wang; Jian-Chun Peng; Lin-Sheng Zhan
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

Review 3.  Epidemiology of HCV infection in the Central European region.

Authors:  Petr Urbánek; Pavol Kristian; Michael Makara; Bela Hunyady; Krzysztof Tomasiewicz
Journal:  Clin Exp Hepatol       Date:  2016-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.